Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
ImmunoGen, Inc. | SVP AND CFO | Stock Option (Right to Buy) | 124K | $564K | $4.56 | Nov 14, 2022 | Direct |
Mural Oncology plc | Director | Ordinary Shares | 10K | $32.1K | $3.21 | Aug 14, 2024 | Direct |
Mural Oncology plc | Director | Stock Option (right to buy) | 8.46K | $28.3K | $3.35 | May 30, 2024 | Direct |
Cerevel Therapeutics Holdings, Inc. | Chief Financial Officer | Common Stock | 0 | $0 | $41.18 | Aug 1, 2024 | Direct |
Cerevel Therapeutics Holdings, Inc. | Chief Financial Officer | Restricted Stock Units | 0 | $0 | $41.18 | Aug 1, 2024 | Direct |
Cerevel Therapeutics Holdings, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 0 | Aug 1, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
MURA | Mural Oncology plc | Aug 14, 2024 | 1 | $32.1K | 4 | Aug 15, 2024 | Director |
CERE | Cerevel Therapeutics Holdings, Inc. | Aug 1, 2024 | 3 | $0 | 4 | Aug 5, 2024 | Chief Financial Officer |
MURA | Mural Oncology plc | May 30, 2024 | 1 | $0 | 4/A | Jun 5, 2024 | Director |
MURA | Mural Oncology plc | May 30, 2024 | 1 | $28.3K | 4 | Jun 3, 2024 | Director |
CERE | Cerevel Therapeutics Holdings, Inc. | Jan 19, 2024 | 1 | $0 | 4 | Jan 23, 2024 | Chief Financial Officer |
CERE | Cerevel Therapeutics Holdings, Inc. | Dec 19, 2023 | 3 | -$572K | 4 | Dec 21, 2023 | Chief Financial Officer |
MURA | Mural Oncology plc | Dec 14, 2023 | 1 | $0 | 4 | Dec 18, 2023 | Director |
MURA | Mural Oncology plc | Oct 31, 2023 | 0 | $0 | 3 | Nov 7, 2023 | Director |
CERE | Cerevel Therapeutics Holdings, Inc. | Jun 1, 2023 | 2 | $0 | 4 | Jun 5, 2023 | Chief Financial Officer |
CERE | Cerevel Therapeutics Holdings, Inc. | May 15, 2023 | 0 | $0 | 3 | May 19, 2023 | Chief Financial Officer |
IMGN | ImmunoGen, Inc. | May 20, 2022 | 2 | $0 | 4 | Dec 27, 2022 | SVP AND CFO |
IMGN | ImmunoGen, Inc. | Feb 4, 2022 | 1 | $1.92M | 4 | Feb 8, 2022 | SVP & Chief Financial Officer |